Nuwellis (NASDAQ:NUWE) Earns “Buy” Rating from Roth Mkm

Roth Mkm restated their buy rating on shares of Nuwellis (NASDAQ:NUWE) in a report released on Tuesday morning, Benzinga reports. They currently have a $17.00 price objective on the stock.

Separately, Roth Capital upgraded shares of Nuwellis to a strong-buy rating in a research note on Monday, July 29th.

Nuwellis Trading Down 6.5 %

Shares of NASDAQ NUWE traded down $0.13 during trading hours on Tuesday, reaching $1.88. The stock had a trading volume of 158,433 shares, compared to its average volume of 230,661. The firm has a 50-day moving average of $4.45 and a 200-day moving average of $10.25. The firm has a market cap of $970,080.00, a price-to-earnings ratio of -0.01 and a beta of 0.44. Nuwellis has a fifty-two week low of $1.79 and a fifty-two week high of $92.75.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.